A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL)
Autor: | Pascale Andre, Norbert Vey, Anthony Gonçalves, Gilles Salles, Sophie Lebouvier-Sadot, Arnaud Pigneux, Dominique Berton-Rigaud, Robert Zerbib, Aude Charbonnier, Jaafar Bennouna, Florence Broussais, Lionel Karlin, Thomas Prebet, Nicolas Boissel, Delphine Marie, Renaud Buffet, Jerome Rey |
---|---|
Rok vydání: | 2015 |
Předmět: | |
Zdroj: | Journal of Clinical Oncology. 33:3065-3065 |
ISSN: | 1527-7755 0732-183X |
Popis: | 3065 Background: Inhibitory Killer Immunoglobulin-like receptors (KIRs) negatively regulate the killing, by NK cells, of tumors expressing their HLA class I ligands. We showed safety of 1st generat... |
Databáze: | OpenAIRE |
Externí odkaz: |